Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: Frank Stein who wrote (180)	4/29/1998 4:08:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 579

Frank: He's talking about the BMY project....... Inhibition of A[beta] Peptide Formation In Vitro and In Vivo Jeffrey Anderson, Ph.D., Research Scientist, SIBIA Neurosciences, Inc. We have studied numerous compounds which alter APP catabolism in a manner resulting in reduced A[beta] peptide formation in vitro. Some of these compounds appear to modulate [beta]-secretase activity, while others work by a mechanism consistent with modulation of [gamma]-secretase. Recent studies involving distinct lines of transgenic mice have shown that some of these molecules are highly effective at inhibiting the proteolytic generation of the A[beta] peptide from APP in vivo. These experiments will be discussed in detail. Rick